CURE’s myeloproliferative neoplasms (MPN) page is an extensive resource of cancer information featuring the latest MPN news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on myeloproliferative neoplasms.
September 15th 2023
The FDA approved Ojjaara for intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia), in adults with anemia.